mitoxantrone has been researched along with Peritoneal Carcinomatosis in 20 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 9.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "A retrospective analysis of intraperitoneal mitoxantrone instillation therapy for malignant ascites in advanced breast and gynecologic pelvic cancers was performed to confirm the efficacy and safety of this therapy." | 8.82 | Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. ( Holtappels, M; Leder, G; Link, KH; Roitman, M; Runnebaum, I; Staib, L; Urbanzyk, H, 2003) |
| "We investigated the therapeutic efficiency of sulfonate-modified polyvinyl alcohol beads loaded with doxorubicin, irinotecan or mitoxantrone in vitro and in vivo in a model of experimental peritoneal carcinomatosis (PC)." | 7.75 | Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. ( Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V, 2009) |
| "A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment." | 7.68 | Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992) |
| "The aim was to determine the recommended dose of combined chemotherapy with mitoxantrone and uracil/tegafur (Phase I part) and to clarify its efficacy and safety in patients with advanced hepatocellular carcinoma at the recommended dose (Phase II part)." | 5.15 | A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma. ( Furuse, J; Ikeda, M; Ishii, H; Mitsunaga, S; Morizane, C; Nakachi, K; Okusaka, T; Suzuki, E; Ueno, H, 2011) |
| "A retrospective analysis of intraperitoneal mitoxantrone instillation therapy for malignant ascites in advanced breast and gynecologic pelvic cancers was performed to confirm the efficacy and safety of this therapy." | 4.82 | Intraperitoneal chemotherapy with mitoxantrone in malignant ascites. ( Holtappels, M; Leder, G; Link, KH; Roitman, M; Runnebaum, I; Staib, L; Urbanzyk, H, 2003) |
| "We investigated the therapeutic efficiency of sulfonate-modified polyvinyl alcohol beads loaded with doxorubicin, irinotecan or mitoxantrone in vitro and in vivo in a model of experimental peritoneal carcinomatosis (PC)." | 3.75 | Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer. ( Faissner, R; Gasimova, L; Keese, M; Lewis, A; Löhr, M; Samel, S; Schwenke, K; Shang, E; Yagublu, V, 2009) |
| "A 44-year-old man who had achieved a complete remission of malignant peritoneal mesothelioma after the intraperitoneal administration of 25 mg/m2 mitoxantrone presented with clinical and radiological signs of intestinal obstruction suggestive of recurrent disease at about 2 years following the initial treatment." | 3.68 | Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone. ( Gallee, MP; Kroon, BB; Rodenhuis, S; Taal, BG; Vlasveld, LT, 1992) |
| "35 ovarian cancer patients with ascites have been treated intraperitoneally with mitomycin C or mitoxantrone or interferon beta or tumor necrosis factor (TNF)." | 3.68 | [Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms]. ( Chronides, A; Diedrich, K; Krebs, D; Mallmann, P; Wagner, U; Werner, A, 1991) |
| " In the first trial, CDDP dosing was established as 90 mg/m2 with a perfusate time of 90 minutes and temperature of 41 degrees C." | 1.34 | Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. ( Benjamin, RS; Chase, JL; Cormier, JN; Feig, BW; Griffin, JR; Hunt, KK; Lim, SJ; Mansfield, PF; Pisters, PW; Pollock, RE, 2007) |
| "Patients with peritoneal carcinomatosis of various origin underwent surgery, including intestinal resections, with minimal residual disease." | 1.31 | Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study. ( Civalleri, D; De Cian, F; DeCian, F; Esposito, M; Lunardi, G; Pastrone, I; Steinweg, M; Vannozzi, MO; Viale, M, 2002) |
| "treatment with mitoxantrone." | 1.28 | Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration. ( Dubbelman, R; McVie, JG; Nagel, JD; ten Bokkel Huinink, WW; Varossieau, FJ, 1992) |
| " We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i." | 1.27 | Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation. ( Blöchl-Daum, B; Ehninger, G; Eichler, HG; Günther, E; Jakesz, R; Proksch, P; Rainer, H; Salzer, H; Schüller, J; Steger, G, 1987) |
| " We have carried out studies to establish maximum tolerated doses as well as pharmacokinetic studies with i." | 1.27 | Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation. ( Blöchl-Daum, B; Ehninger, G; Eichler, HG; Günther, E; Jakesz, R; Proksch, B; Rainer, H; Salzer, H; Schüller, J; Steger, G, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (25.00) | 18.7374 |
| 1990's | 6 (30.00) | 18.2507 |
| 2000's | 8 (40.00) | 29.6817 |
| 2010's | 1 (5.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Keese, M | 1 |
| Gasimova, L | 1 |
| Schwenke, K | 1 |
| Yagublu, V | 1 |
| Shang, E | 1 |
| Faissner, R | 1 |
| Lewis, A | 1 |
| Samel, S | 1 |
| Löhr, M | 1 |
| Kehoe, SM | 1 |
| Williams, NL | 1 |
| Yakubu, R | 1 |
| Levine, DA | 1 |
| Chi, DS | 1 |
| Sabbatini, PJ | 1 |
| Aghajanian, CA | 1 |
| Barakat, RR | 1 |
| Abu-Rustum, NR | 1 |
| Suzuki, E | 1 |
| Furuse, J | 1 |
| Ikeda, M | 1 |
| Ishii, H | 1 |
| Okusaka, T | 1 |
| Nakachi, K | 1 |
| Mitsunaga, S | 1 |
| Ueno, H | 1 |
| Morizane, C | 1 |
| Link, KH | 2 |
| Roitman, M | 1 |
| Holtappels, M | 1 |
| Runnebaum, I | 1 |
| Urbanzyk, H | 1 |
| Leder, G | 1 |
| Staib, L | 2 |
| Schmidt, U | 1 |
| Dahlke, MH | 1 |
| Klempnauer, J | 1 |
| Schlitt, HJ | 1 |
| Piso, P | 1 |
| Lim, SJ | 1 |
| Cormier, JN | 1 |
| Feig, BW | 1 |
| Mansfield, PF | 1 |
| Benjamin, RS | 1 |
| Griffin, JR | 1 |
| Chase, JL | 1 |
| Pisters, PW | 1 |
| Pollock, RE | 1 |
| Hunt, KK | 1 |
| Genne, P | 1 |
| Olsson, NO | 1 |
| Gutierrez, G | 1 |
| Duchamp, O | 1 |
| Chauffert, B | 1 |
| Hepp, G | 1 |
| Butzer, U | 1 |
| Böhm, W | 1 |
| Beger, HG | 1 |
| Volz, J | 1 |
| Volz-Köster, S | 1 |
| Kanis, S | 1 |
| Klee, D | 1 |
| Ahlert, C | 1 |
| Melchert, F | 1 |
| Civalleri, D | 1 |
| Vannozzi, MO | 1 |
| De Cian, F | 1 |
| DeCian, F | 1 |
| Lunardi, G | 1 |
| Steinweg, M | 1 |
| Pastrone, I | 1 |
| Viale, M | 1 |
| Esposito, M | 1 |
| Verschraegen, CF | 1 |
| Vlasveld, LT | 1 |
| Taal, BG | 1 |
| Kroon, BB | 1 |
| Gallee, MP | 1 |
| Rodenhuis, S | 1 |
| Nagel, JD | 2 |
| Varossieau, FJ | 1 |
| Dubbelman, R | 1 |
| ten Bokkel Huinink, WW | 1 |
| McVie, JG | 2 |
| Werner, A | 1 |
| Mallmann, P | 1 |
| Chronides, A | 1 |
| Diedrich, K | 1 |
| Wagner, U | 1 |
| Krebs, D | 1 |
| Los, G | 1 |
| Markman, M | 1 |
| Reichman, B | 1 |
| Hakes, T | 1 |
| Hoskins, W | 1 |
| Rubin, S | 1 |
| Jones, W | 1 |
| Lewis, JL | 1 |
| Kuhn, K | 1 |
| Purea, H | 1 |
| Selbach, J | 1 |
| Westerhausen, M | 1 |
| Blöchl-Daum, B | 3 |
| Eichler, HG | 3 |
| Rainer, H | 3 |
| Jakesz, R | 2 |
| Salzer, H | 2 |
| Steger, G | 3 |
| Schüller, J | 2 |
| Günther, E | 2 |
| Proksch, P | 1 |
| Ehninger, G | 3 |
| Proksch, B | 1 |
| Mader, R | 1 |
| Dittrich, C | 1 |
| Moser, K | 1 |
2 reviews available for mitoxantrone and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Intraperitoneal chemotherapy with mitoxantrone in malignant ascites.
Topics: Adult; Aged; Aged, 80 and over; Ascites; Carcinoma; Chemotherapy, Adjuvant; Dose-Response Relationsh | 2003 |
Intracavitary therapies for mesothelioma.
Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adj | 2001 |
2 trials available for mitoxantrone and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
A phase I/II study of combined chemotherapy with mitoxantrone and uracil/tegafur for advanced hepatocellular carcinoma.
Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carci | 2011 |
Coupling of mitoxantrone to poly(I).poly(C) reduces absorption after intraperitoneal administration.
Topics: Absorption; Double-Blind Method; Female; Humans; Infusions, Parenteral; Male; Middle Aged; Mitoxantr | 1987 |
16 other studies available for mitoxantrone and Peritoneal Carcinomatosis
| Article | Year |
|---|---|
Doxorubicin and mitoxantrone drug eluting beads for the treatment of experimental peritoneal carcinomatosis in colorectal cancer.
Topics: Animals; Antineoplastic Agents; Apoptosis; Camptothecin; Cell Line, Tumor; Chemoembolization, Therap | 2009 |
Incidence of intestinal obstruction following intraperitoneal chemotherapy for ovarian tubal and peritoneal malignancies.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Catheters, Indwelling; Cisplatin; Fallo | 2009 |
Perioperative morbidity and quality of life in long-term survivors following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Cisplatin; Combined Modality Therapy; Female; Health Status; Hum | 2005 |
Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis.
Topics: Adult; Aged; Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cisplatin; Clinical Tr | 2007 |
Liposomal mitoxantrone for the local treatment of peritoneal carcinomatosis induced by colon cancer cells in mice.
Topics: Animals; Carcinoma; Colonic Neoplasms; Drug Carriers; Electrochemistry; Female; Liposomes; Male; Mic | 1994 |
Intraperitoneal regional chemotherapy with mitroxantrone.
Topics: Antineoplastic Agents; Ascites; Humans; Mitoxantrone; Peritoneal Neoplasms | 1996 |
Modulation of tumor-induced lethality after pneumoperitoneum in a mouse model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Disease Models, Animal; Fema | 2000 |
Intraperitoneal mitoxantrone: a feasibility and pharmacokinetic study.
Topics: Adult; Carcinoma; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Sched | 2002 |
Intestinal obstruction due to diffuse peritoneal fibrosis at 2 years after the successful treatment of malignant peritoneal mesothelioma with intraperitoneal mitoxantrone.
Topics: Adult; Biopsy; Fibrosis; Humans; Injections, Intraperitoneal; Intestinal Obstruction; Jejunal Diseas | 1992 |
Clinical pharmacokinetics of mitoxantrone after intraperitoneal administration.
Topics: Abdominal Neoplasms; Adult; Breast Neoplasms; Female; Humans; Injections, Intraperitoneal; Male; Mes | 1992 |
[Locoregional ascites therapy with cytostatic drugs and immune modulators in gynecologic neoplasms].
Topics: Ascites; Breast Neoplasms; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Interferon- | 1991 |
Anti-tumor effect of cisplatin, carboplatin, mitoxantrone, and doxorubicin on peritoneal tumor growth after intraperitoneal and intravenous chemotherapy: a comparative study.
Topics: Animals; Antineoplastic Agents; Body Weight; Carboplatin; Cisplatin; Doxorubicin; Injections, Intrap | 1990 |
Intraperitoneal chemotherapy as treatment for ovarian carcinoma and gastrointestinal malignancies: the Memorial Sloan-Kettering Cancer Center experience).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Evaluation; Etoposide; Female; Fluor | 1989 |
Treatment with locally applied mitoxantrone.
Topics: Catheters, Indwelling; Female; Humans; Infusions, Parenteral; Male; Mediastinal Neoplasms; Mitoxantr | 1989 |
Phase-I study of intraperitoneal mitoxantrone--clinical and pharmacokinetic evaluation.
Topics: Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Male; Mitoxantro | 1987 |
Escalating dose regimen of intraperitoneal mitoxantrone: phase I study--clinical and pharmacokinetic evaluation.
Topics: Adult; Aged; Drug Evaluation; Female; Gastrointestinal Neoplasms; Humans; Infusions, Parenteral; Mal | 1988 |